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SummarZ The impact of recombinant human tumour necrosis factor-alpha (1 cg kg-' to I mgkg-';
6.6 x 10 U mg protein- ) on blood flow, oxygen consumption and growth of a moderately TNF-sensitive rat
tumour (DS-carcinosarcoma) was studied. Tumour growth was stimulated at low TNF doses (I and
10 gg kg- ) and significantly retarded at higher TNF dose levels (0.1 and I mg kg- ). Growth changes were
concomitant with variations in oxygen consumption, lactate release and acidification of the metabolic
micromilieu. Both single and repeated application of low TNF doses (I -10 g kg'- i.v.) increased tumour
perfusion whereas single administration of high TNF dose levels (0.1 1 mg kg-' i.v.) reduced tumour blood
flow. After repeated application of high TNF doses tumours shrank to such small sizes that perfusion
measurements could not be performed within the observation period of two weeks. It is concluded that TNF
effects on solid tumours are at least partially mediated by changes in tumour perfusion. Thus, an altered
tumour sensitivity towards other treatment modalities, e.g. irradiation, chemotherapy or hyperthermia, can be
expected after TNF therapy. A beneficial TNF effect would critically depend on the dose level employed and
on the sequence and timing of various combination regimes.
Tumour necrosis factor-x was discovered in tumour-bearing
mice as an endotoxin-induceable serum factor causing 'haemo-
rrhagic' tumour necrosis (Carswell et al., 1975). Genetic
sequence analysis indicated that TNF and cachectin, a serum
factor which can cause wasting in chronic disease, are iden-
tical molecules (Beutler & Cerami, 1986). Considering anti-
tumour mechanisms only, cytostatic or cytolytic activities are
already evident in vitro (Sugarman et al., 1985; Creasey et al.,
1987; Lewis et al., 1987). In vivo, TNF-x may indirectly
enhance its antitumour effect via incompletely characterised
vascular actions (Manda et al., 1987; Watanabe et al.,
1988a). Probably, both mechanisms can lead to tumour re-
gression (Shimomura et al., 1988). On the other hand, TNF-a
can promote angiogenesis in living tissues even though it
inhibits endothelial cell growth in vitro (Frater-Schroeder et
al., 1987; Leibovich et al., 1987). These partly contradictory
findings finally all imply changes of the nutritive tumour
perfusion which in turn dictates therapeutically relevant para-
meters of the cellular micromilieu (Kallinowski et al., 1989).
Thus, different TNF-related flow variations might at least
partially explain an inconsistent effectiveness of TNF in the
clinical situation (Spriggs et al., 1987). In a step towards
further understanding TNF actions we have examined the
response of tumour perfusion and proliferation to various
TNF doses. Changes in the metabolism of tumour cells (02
and glucose uptake, lactate release, extracellular pH) were
also followed during TNF treatment. A better knowledge of
TNF effects might provide a rationale for combination with
other treatment modalities including radiation, chemotherapy
and hyperthermia (Selby et al., 1987).
Materials and methods
Animals
Sprague-Dawley rats were bred and maintained in the Dep-
artment of Applied Physiology (University of Mainz, FRG).
The animals were kept in pairs in Macrolon cages with
dust-free wood bedding. They fed on Altromin 1324 standard
diet for rats (Altromin, Lage/Lippe, FRG) and water ad
libitum. Room temperature was adjusted to 22 ± 1°C at a
relative humidity of 55 ± 5% (12 h light/dark cycles).
Tumour
DS-carcinosarcoma cells were serially passaged in the peri-
toneal cavity of SD-rats. TNF-sensitivity in viiro was tested
using DS-carcinosarcoma cells in suspension culture (RPMI
1640 medium, Sigma Chemicals, St Louis, MO, USA; 5%
CO2 in air; 10% fetal calf serum, Gibco BRL, Bethesda,
MD, USA). 104 cells were plated into microtitre wells 12 h
before various TNF concentrations were added. The specific
activity of rhTNF-a was 6.6 x 106 U mg protein-' (BASF/
Knoll AG, Ludwigshafen, FRG). The mean endotoxin level
was <0.025 ng mg protein-' as determined by Limulus
amoebocyte lysate assay. After 48 h, cell density was
evaluated. Reduction of growth by 50% was found at 100 ng
rhTNF-x ml-' (L929 cells: approx. I ng TNF ml-'; MCF-7
cells: approx. 10 ng TNF ml-'). Consequently, DS-
carcinosarcoma cells were classified as moderately TNF-
sensitive according to Creasey cl al. (1987).
Investigations on ascites tumours
Tumours were implanted by i.p. injection of 0.7 ml ascites
(approx. 107 cells ml-'). rhTNF-a (1- 1000 lg kg- body
weight in 1 ml PBS) was given every 12 h i.p. beginning 8 h
after tumour implantation. Injections of PBS served as cont-
rol. After a growth period of 6 days, i.e. at the end of the
exponential growth period of control tumours, the animals
were killed by cervical dislocation and weighed before and
after complete removal of the ascites from the peritoneal
cavity. The total amount of ascites was obtained as the
difference of both measurements. The percentage of cells in
the ascitic fluid was determined by microcapillary centrifuga-
tion, and the cellular wet weight was calculated. The number
of cells per unit volume of ascitic fluid as well as the dia-
meters of tumou'r cells were assessed using a calibrated ret-
icule in a microscope with 400 fold magnification. The ascites
cells were differentiated into intact tumour cells, tumour cell
ghosts, erythrocytes, monocytes, lymphocytes and polymor-
phonuclear leukocytes using four smears per animal
(100-200 cells per smear). The smears were stained with
Gugol Blue Wright-Giemsa stain (Gugol Stain Co., Long
Island City, NY, USA). The cellular oxygen consumption
was measured according to Mueller-Klieser et al. (1986).
Glucose and lactate concentration in the ascitic fluid were
determined using enzymatic tests (glucoquant glucose; mono-
test lactate; Boehringer Mannheim, Mannheim, FRG). pH
values in the ascitic fluid were measured with a blood gas
analyser (type MT 33, Eschweiler, Kiel, FRG).
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Investigations on solid tumours
Volume growth curves of DS-carcinosarcoma, implanted into
the subcutis of the hind foot dorsum (s.c. injection of 0.4 ml
ascites; approx, I07 cells ml-') were obtained by daily mea-
surements of the three orthogonal diameters and subsequent
calculation of an ellipsoid. Tumour-bearing animals were
treated with daily injections of rhTNF-a (1 -1000#g kg-'
body weight) into the tail vein starting 24h after tumour
implantation. PBS injections were used as controls.
In a separate series, tumour blood flow was determined
using the krypton-85 clearance technique (Vaupel et al.,
1977). Here, the animals were anaesthetised with Na-pento-
barbitone (35-40 mg kg-' i.p., Nembutal, Ceva, Paris,
France). A catheter in the left carotid artery permitted the
continuous monitoring of the mean arterial blood pressure
and the application of the radioactive tracer. A Geiger-
Mueller counting tube was placed over the tumours without
compressing the tumour tissue. After i.a. injection of 85Kr
dissolved in 0.9% NaCl solution (injection of 0.1 ml;
37 MBq ml-'; Amersham Buchler; Braunschweig, FRG) the
subsequent washout was recorded. Blood flow was calculated
from the washout curves (Vaupel et al., 1977).
In a first step, blood flow changes were evaluated 4 h after
single TNF doses (I gg to 1 mg rhTNF-ax kg-' i.v.; average
tumour size approx. 1.0 g). Then, possible influences of tu-
mour size on flow reduction after high TNF doses (1 mg
rhTNF-akg-' i.v.) were investigated using small and larger
DS-carcinosarcomas (tumour sizes around 0.6 and 1.3 g, res-
pectively). Next, the time course of a possible flow decrease
was evaluated. Here, blood flow was measured before and in
30 min intervals up to 4 h after i.v. injection of rhTNF-a
(1 mg kg-' in 1 ml PBS) or PBS (1 ml kg-'). In a final series,
the effect of repeated treatment with rhTNF-x on tumour
blood flow was assessed (mean tww: 0.6- 1.0 g; growth per-
iod: 6-8 days). Since tumour blood flow critically depends
on tumour size, PBS-treated tumours of similar sizes (tumour
age: 7.0 ± 0.3 days, tww: 0.8 ± 0.1 g) were used as controls.
Efje(t of rhTNF-a on liver andkidney bloodflow
Acute changes of normal organ blood flow were evaluated
4 h after i.v. injection of high TNF doses (1 mg kg-'). Liver
perfusion was determined by "5Kr clearance (Vaupel et al.,
1978). Global kidney perfusion was measured after cannula-
tion of the renal vein by timed collection of the venous
outflow (Guenther et al., 1974; Arendshorst et al., 1975). As
controls, both untreated and PBS-treated animals in (1 ml
kg-' bw i.v.) were used.
Statistical evaluation
Descriptive statistical parameters were routinely calculated.
Two-tailed t test and Mann-Whitney U test were used for
evaluation of statistically significant differences between var-
ious treatment groups. In the following, means ± s.e. are
given if not indicated otherwise.
Results
EfJect ol TNF on asc-ites tumours
Tumour growth was markedly reduced after treatment with
high TNF doses (0.1 and 1.0 mg kg-' i.p.). Administration of
low TNF doses (1 and 10 jig kg-' i.p.) was followed by a
slight increase both in the ascitic volume and in the total
weight of the ascites cells (Figure 1). Similarly, the absolute
number of ascites cells was significantly decreased after treat-
ment with high TNF doses (P<0.01, Table I). After treat-
ment with small TNF doses, cell numbers varied only slightly
compared to control counts (Table I).
The growth changes were concomitant with an immigra-
tion of host cells into the ascites and an accumulation of
tumour cell debris (Table I, Figure 2). Hereby, small TNF
doses already led to morphological changes and the disrup-
tion of tumour cell membranes. The pronounced invasion of
micro- and macrophages into the peritoneal cavity at high
TNF doses probably contributed to the destruction of tu-
mour cells. Cellular TNF effects were further evidenced by
monitoring the diameters of malignant cells. During control
conditions, the mean cell diameter is 28.7 ± 0.7 ,.m. The
intraperitoneal application of small TNF doses reduced this
value to 26.3 + 0.9, to 25.3 ± 0.7 and to 23.0 ± 0.9 gm at 1,
10 and 100ggkg-' TNF (P<0.005). Higher TNF levels
were followed by an even more marked reduction to values
of 21.0±0.5gim (P<0.0001).
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Figure 1 Influence of TNF treatment on total ascites weight
(circles) and total cellular wet weight (dots) 6 days after implanta-
tion, i.e. at the end of the exponential growth period. TNF doses
were administered i.p. every 12 h. PBS application served as
control. Numbers in parentheses indicate the number of tumours
investigated. Values are means ± s.e. *P<0.05; **P<0.01;
***P<0.001 .
Table I Absolute cell numbers ( x 109) in ascites DS-carcinosarcomas
after 6 days of treatment
TNF concentration 0 1 10 100 1000
Total cell count 8.19 8.51 7.60 4.50 1.30
Tumour cells 7.01 6.25 5.07 2.72 0.74
Tumour cell ghosts 0.52 1.10 1.07 0.54 0.15
Granulocytes 0.39 0.70 1.00 0.83 0.30
Lymphocytes 0.19 0.29 0.33 0.31 0.07
Monocytes 0.08 0.17 0.13 0.10 0.04
rhTNF-a(jLg kg-' in I ml kg-' PBS) was injected every 12 h into the
peritoneal cavity. Values are means from 3-4 animals.
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Figure 2 Proportion of different cell types in the DS-
carcinosarcoma ascites 6 days after tumour implantation. TNF
was given i.p. every 12 h. The values are averages of nine ascites
tumours in each group. In each tumour, several hundred cells
were differentiated.
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Growth changes upon TNF application were paralleled by
alterations in oxygen consumption rates (Figure 3). At higher
TNF doses, a marked reduction of the 02 uptake was obser-
ved whereas the oxygen consumption was increased at low
TNF doses. Only traces of glucose were found in the ascitic
fluid in all treatment groups indicating an avid glucose con-
sumption under all conditions. The production of lactate
somewhat increased at low TNF dose levels. At higher TNF
doses the reduction of growth rates was concomitant with a
decreased lactate release leading to lower lactate levels in the
ascitic fluid (Figure 4). Extracellular pH values generally
followed changes of the ascites lactate concentrations (Figure
4).
Effect of TNF on solid tumours
The growth rate of solid tumours was markedly retarded
upon application of high TNF doses. After application of
low TNF doses, tumour volumes increased at faster rates
(Figure 5).
These growth changes were concomitant with a modula-
tion of tumour perfusion. Blood flow of s.c. DS-carcino-
saccomas after repeated rhTNF-x administration, starting
24 h after tumour implantation, was assessed in order to
evaluate a possible alteration of tumour neovascularisation
by TNF treatment in vivo. Since the growth stage critically
influences tumour perfusion, flow changes were evaluated at
comparable tumour sizes (about 0.8 g). This necessarily imp-
lies different growth periods. Blood flow of PBS-treated tu-
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Figure 3 Oxygen consumption rate (Qo2) per unit weight of
DS-carcinosarcoma ascites cells 6 days after tumour implantation
(end of exponential growth period). rhTNF-x was injected i.p.
every 12 h. The number of investigations is given in parentheses.
Values are means ± s.d. ***P<0.001.
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Figure 5 Volume growth curves of s.c. DS-carcinosarcomas
treated with various rhTNF-a doses. TNF was injected once daily
into the tail vein.
mours after a growth period of 7 days was 0.87 + 0.07 ml g-
min '. After daily application of lower TNF doses, an in-
creased perfusion was observed (growth period: 6 days).
Here, TBF was 1.19 ± 0.10 ml g-' mmn after 1 ysg kg-',and
1.17±+0.08mlg- min'} after l01tgkg1t Higher TNF doses
retarded tumour growth as described above. Considering
sizes comparable to that of control tumours, a slight reduc-
tion of tumour blood flow was obvious after application of
0.1 mg kg-' (0.73 ± 0.04 ml g-'min' growth period: X
days). Mean arterial blood pressures of tumour-bearing
animals in all experimental groups were not significantly
different (115- 125 mmHg). Sizes of tumours treated with
highest TNF doses (1 mgkg'" i.v.) were reduced to such an
extent (<0.3g) that flow measurements could not be per-
formed within the observation period. This time span was
limited to two weeks by the appearance of TNF-binding
antibodies in rats after daily application of rhTNF-e (Keil-
hauer, BASF/Knoll AG, personal communication).
Modulation of tumour perfusion after single TNF treat-
ment might critically influence sequence and timing of com-
bination therapy. In this study, dose-dependent changes of
tumour blood flow were observed after single i.v. administra-
tion of rhTNF-a. Here, tumour perfusion was reduced 4h
after high TNF doses and elevated at the same time after low
TNF dose levels (Figure 6). Mean arterial blood pressure
(MABP) of control animals was 113 ± 3 mmHg. Compared
to these values, low TNF doses were followed by an eleva-
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Figure 4 pH values (dots) and lactate concentrations (circles) in
the ascitic fluid of DS-carcinosarcomas after a growth period of 6
days. rhTNF-a was injected i.p. every 12 h. The number of
investigations is given in brackets. Values are means ± s.d.
Figure 6 Blood flow (TBF) changes in solid DS-carcinosarcomas
4 h after single i.v. rhTNF-a application compared to control (C)
tumours. Tumour wet weights were about 0.8 g (growth periods
6-8 days). Levels of significance are related to control tumours.
Values are means ± s.e. *P<0.01; **P<0.0001.
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tion of perfusion pressure (124 ± 3 mmHg, P<0.05) whereas
high TNF doses led to a MABP reduction (101 ± 2 mmHg,
P<0.05).
The flow changes were found to be independent of the
tumour size (0.5-1.3 g). Both in small and larger DS-carcino-
sarcomas, tumour blood flow decreased to 30-40% of con-
trol values after administration of high TNF doses (1 mg
kg-' i.v.). The time course of flow reductions at these dose
levels was evaluated using tumours with wet weights between
0.8 and 1.0 g. PBS administration (1 ml kg-' i.v.) served as
control. In both groups, the first measurements were ob-
tained 15 min after surgical procedures. At this time, without
drug administration, the flow values were almost identical
(PBS group: 0.81 ± 0.07 ml g-' min-'; TNF group:
0.84 ± 0.06 ml g-' min). After measurement of baseline TBF,
drug administration was performed. Thirty minutes later,
blood flow was reduced by approx. 10% in both groups.
Thereafter, a marked reduction of blood flow occurred in
TNF-treated tumours reaching 50% of baseline values 90
min after injection of the drug. Between 90 and 240 min after
TNF administration no further flow change was observed. In
the control group, a maximum TBF drop of 25% was de-
tected during the observation period, the actual flow values
being not significantly different from baseline data. Mean
arterial blood pressure was 100-120mmHg in both groups
without marked changes during the observation period.
Blood flow of liver and kidney was 1.3 ± 0.1 and
3.8 ± 0.5 ml g-' min-', respectively. Four hours after a single
injection of high TNF doses (1.0 mg kg-' i.v.), perfusion
rates were not significantly different from control values.
Side-effeccts ofrhTNF-a treatment
Significant side-effects were observed only in animals treated
with the highest TNF dose used (1.0 mg kg-'). Here, a haem-
orrhagic diarrhea developed after single TNF administra-
tion. Concomitantly, there was a mild drop of mean arterial
blood pressure (100 vs 120 mmHg) and a weight loss of
approx. 14%. The slight increase in mean arterial hematocrit
(0.48 vs 0.44) has to be taken as evidence for an increased
extravasation of plasma due to an enhanced vascular perm-
eability after TNF treatment. The overall lethality observed
at the highest TNF dose used was approx. 10% for animals
treated with daily intravenous injections and 20% for ani-
mals with intraperitoneal TNF administration twice daily.
Discussion
DS-carcinosarcoma cells are moderately TNF sensitive in
vitro. In 'ii'o, tumour response depends on TNF dose. A
somewhat increased volume growth was found at low TNF
concentrations whereas a significant reduction occurred at
high TNF doses. Enhanced proliferation rates upon TNF
treatment were previously reported for normal cells in vitro
(Sugarman et at., 1985; Creasey et al., 1987). Lewis et al.
(1987) demonstrated a dose-dependent growth modulation of
tumour cells in vitro. TNF further acts as an autocrine
growth factor for chronic B-cell malignancies (Cordingley et
al., 1988). Based on the ascites data, it can be concluded that
the apparent increase in tumour volume at low TNF doses
observed in this study is probably due to a pronounced
immigration of host cells, predominantly polymorphonuclear
leukocytes. Here, TNF could be directly chemotactic (Ming
et al., 1987) or could lyse tumour cells leading to the release
of chemotactic stimuli. The growth reduction at high TNF
concentrations is caused by direct effects on tumour cells
(Sugarman et al., 1985; Creasey et al., 1987), action of
activated host cells (Shau, 1988), a modulation of tumour-
specific immunity (Talmadge et al., 1988) and metabolic
alterations of host and tumour cells as demonstrated here.
Changes in haemodynamic and vascular functions further
alter the response of solid tumours to TNF treatment. After
single administration of low TNF doses, a rise in perfusion
pressure led to an increased tumour blood flow. The eleva-
tion of blood pressure was probably caused by a rise in
cardiac output as a sign of a hypercirculatory state (Tracey et
al., 1986). The flow reduction observed after single administ-
ration of high TNF doses can be caused by both systemic
and tumour-specific mechanisms. A flow chart depicting pos-
sible pathways is given in Figure 7. Considering systemic
effects, high TNF doses are followed by a reduction of
perfusion pressure which could indicate the initiation of a
'septic shock syndrome' (Tracey et al., 1986). In keeping with
this syndrome, an increased vascular permeability leads to a
systemic haemoconcentration, an elevated blood viscosity
and a reduced tumour perfusion. As a further consequence, a
reduction in total blood volume and a decreased cardiac
output have to be expected. Due to the lack of functioning
lymphatics, fluid leakage into the tumour interstitium causes
a decreased perfusion pressure and thus, a drop in tumour
blood flow. Considering relatively tumour-specific effects,
thrombi formation in tumour vessels contributes to the re-
duction of tumour perfusion at high TNF doses (Nawroth et
al., 1986; Shimomura et al., 1988). The stimulation of poly-
morphonuclear leukocytes and macrophages (Shau, 1988),
the binding of activated neutrophils to endothelial cells
(Gamble et al., 1985), endothelial cell damage (Movat et al.,
1987), and the release of procoagulant activity (Nawroth et
al., 1986; Bevilacqua et al., 1986) and of interleukin-I (Lock-
sley et al., 1987; Kurt-Jones et al., 1987) are pathophys-
iological mechanisms involved in vascular damage.
After repeated application of low TNF doses, an increased
tumour perfusion concomitant with a rise in perfusion pres-
sure was noted. After high TNF doses, tumours shrank to
such small sizes that valid perfusion measurements could not
be performed. The reduction in tumour volume might be due
to sustained vascular damage or due to cellular effects dis-
cussed above.
So far, phase I clinical trials with TNF doses ranging from
1-7.5 tLg kg-' i.v. indicate only limited efficacy of TNF mono-
therapy (Conkling et al., 1988; Herrmann & Mertelsmann,
1989). Dose-limiting side effects in patients include pyrexia
and hypotension. In rodents, similar side effects of TNF were
observed (Tracey et al., 1986). In our system, single applica-
tion of rhTNF-a at a dose of 1 mg kg-' i.v. was lethal for
about 10% of the animals. Histological examination after
6[Reduction of tumour blood flow
Figure 7 Relevant pathophysiological mechanisms involved in reduction of tumour blood flow after TNF treatment.IN VIVO TARGETS OF rhTNF-a 559
TNF treatment suggests that the gastrointestinal tract is
more TNF sensitive than other tissues (Remick et al., 1987).
Partial tolerance to the gastrointestinal effects of high rh-
TNF-a doses developed when TNF application was repeated
daily (Patton et al., 1987). In good agreement with these data
haemorrhagic diarrhoea with weight loss developed only after
the first TNF application. Furthermore, blood flow of liver
or kidney was not altered after single application of high
TNF doses indicating that, at that time, severe vascular
damage in these organs is unlikely.
The decrease of nutritive blood flow through malignant
tumours leads to ischaemic changes, and to a distinct worsen-
ing of the supply of nutrients and of the energy status of
these tumours, thus contributing to cell killing (Shine et al.,
1989). Furthermore, the changes of the tumour perfusion and
of the regional micromilieu might have sustained impact on
possible combinations with other non-surgical treatment mo-
dalities. The reduction of tumour blood flow markedly
influences the intratumour pharmakokinetics of anti-
proliferative agents and is thus critical for a possible combined
treatment. On the other hand, hyperthermia applied either
locally (Kallinowski et al., 1988) or as whole body treatment
(Haranaka et al., 1987; Watanabe et al., 1988b) may benefit
from a preceding TNF application. It is most likely that an
increased oxygen consumption at low TNF doses or a de-
creased oxygen supply after treatment with high TNF dose
levels worsen tumour tissue oxygenation and thus induce
radiation resistance in vivo. In vitro, no significant benefit of a
combination of radiation therapy and TNF treatment is
evident (Chang & Keng, 1988).
Similar to other lymphokines, there is some specificity of
TNF actions in various species (Fransen et al., 1986). We
chose rats as our tumour hosts since they permit the inves-
tigation of TNF effects in vivo over a wide dose range
(Tracey et al., 1986). It has been demonstrated that species-
specificity can lead to an underestimation of the biological
potency of TNF-a from heterologous sources (Kramer et al.,
1988). Thus, use of recombinant TNF from rat rather than
from human sources might alter quantitative values of the
data presented here, but will probably not alter the qual-
itative mechanisms evaluated.
The authors highly appreciate the help of Dr Kcilhauer, BASF/Kiioll
AG, Ludwigshafen, FRG, who determined the rhTNF-a sensitivity
of the DS-carcinosarcoma cell line in itro. rhTNF-a was a generous
gift from the BASF/Knoll AG, D-6700 Ludwigshafen, FRG.
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